Meyka AI API is live for developers.Start building.
Advertisement
Veracyte, Inc.

Veracyte, Inc. (VCYT) Stock Overview

Explore Veracyte, Inc.’s financial performance, market position, analyst ratings, and future outlook.

VCYTNASDAQ
HealthcareBiotechnology
$48.73
$1.21(2.42%)
U.S. Market opens in 51h 50m
Advertisement

Veracyte, Inc. (VCYT)

Meyka AI Score

Z

Key Financials

Market Cap3.9B
P/E Ratio43.96
EPS (TTM)$1.08
ROE0.07%
Fundamental Analysis

AI Price Forecasts

1 Month$31.74
3 Months$25.15
1 Year Target$45.32

VCYT Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Veracyte, Inc. (VCYT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 74.43, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $45.32.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 43.96 and a market capitalization of 3.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-2.42%
5-Day Change
1.33%
1-Month Change
47.80%
3-Month Change
40.51%
6-Month Change
9.24%
Year-to-Date (YTD) Change
15.75%
1-Year Change
80.62%
3-Year Change
88.002%
5-Year Change
39.47%
All-Time (Max) Change
267.77%

Contact Information

650 243 6300
6000 Shoreline Court, South San Francisco, CA, 94080

Company Facts

824 Employees
IPO DateOct 30, 2013
CountryUS
Actively Trading

Frequently Asked Questions